Axillary node staging for microinvasive breast cancer: Is it justified? Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Carcinoma in Situ
  • Carcinoma, Ductal, Breast
  • Lymph Node Excision
  • Lymph Nodes
  • Neoplasm Recurrence, Local

abstract

  • Our results suggest that SLN biopsy may be justified for DCISM, but is clearly most beneficial to identify a very small subset of DCISM patients (2.7%, with SLN macrometastasis) who could benefit from systemic adjuvant therapy. The benefit of SLN biopsy for patients with SLN micrometastases/ITCs (pN0mi or pN0(i+)) is uncertain, and in these cases ALND does not appear to be warranted. We suggest a wider reappraisal of routine SLN biopsy for DCISM.

publication date

  • October 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1245/s10434-012-2376-5

PubMed ID

  • 22576061

Additional Document Info

start page

  • 3416

end page

  • 21

volume

  • 19

number

  • 11